{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T00:47:19Z","timestamp":1785372439029,"version":"3.55.0"},"reference-count":36,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2012,5,1]],"date-time":"2012-05-01T00:00:00Z","timestamp":1335830400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,5,1]],"date-time":"2012-05-01T00:00:00Z","timestamp":1335830400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100004191","name":"Novo Nordisk","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004191","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004323","name":"Amylin Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004323","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2012,5]]},"DOI":"10.1016\/j.clinthera.2012.02.029","type":"journal-article","created":{"date-parts":[[2012,3,21]],"date-time":"2012-03-21T00:20:17Z","timestamp":1332289217000},"page":"993-1005","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":39,"title":["Review of Linagliptin for the Treatment of Type 2 Diabetes Mellitus"],"prefix":"10.1016","volume":"34","author":[{"given":"Joshua J.","family":"Neumiller","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen M.","family":"Setter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2012.02.029_bib1","first-page":"1249","article-title":"UK prospective diabetes study 16","volume":"44","year":"1995","journal-title":"Diabetes"},{"key":"10.1016\/j.clinthera.2012.02.029_bib2","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1001\/jama.281.21.2005","article-title":"Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49)","volume":"281","author":"Turner","year":"1999","journal-title":"JAMA"},{"key":"10.1016\/j.clinthera.2012.02.029_bib3","doi-asserted-by":"crossref","first-page":"193","DOI":"10.2337\/dc08-9025","article-title":"Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes","volume":"32","author":"Nathan","year":"2009","journal-title":"Diabetes Care"},{"key":"10.1016\/j.clinthera.2012.02.029_bib4","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1111\/j.1432-1033.1993.tb17986.x","article-title":"Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum","volume":"214","author":"Mentlein","year":"1993","journal-title":"Eur J Biochem"},{"key":"10.1016\/j.clinthera.2012.02.029_bib5","doi-asserted-by":"crossref","first-page":"4135","DOI":"10.1021\/jm030628v","article-title":"Dipeptidyl peptidase IV inhibitors for the treatment of diabetes","volume":"47","author":"Weber","year":"2004","journal-title":"J Med Chem"},{"key":"10.1016\/j.clinthera.2012.02.029_bib6","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.regpep.2004.06.001","article-title":"Dipeptidyl peptidase IV inhibitors: how do they work as new antidiabetic agents?","volume":"128","author":"McIntosh","year":"2005","journal-title":"Regul Pept"},{"key":"10.1016\/j.clinthera.2012.02.029_bib7","doi-asserted-by":"crossref","first-page":"6450","DOI":"10.1021\/jm701280z","article-title":"8-(3-(R)-aminopiperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylme thyl)-3,7-dihydropurine-2,6-dione (BI 1356), a highly potent, selective, long-acting, and orally bioavailable DPP-4 inhibitor for the treatment of type 2 diabetes","volume":"50","author":"Eckhardt","year":"2007","journal-title":"J Med Chem"},{"key":"10.1016\/j.clinthera.2012.02.029_bib8","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1177\/0091270008323753","article-title":"Safety, tolerability, pharmacokinetics, and pharmacodynamics of single oral doses of BI 1356, an inhibitor of dipeptidyl peptidase 4, in healthy male volunteers","volume":"48","author":"H\u00fcttner","year":"2008","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2012.02.029_bib9","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1124\/jpet.107.135723","volume":"325","author":"Thomas","year":"2008","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.clinthera.2012.02.029_bib10","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1111\/j.1463-1326.2009.01046.x","article-title":"Pharmacokinetics, pharmacodynamics and tolerability of multiple oral doses of linagliptin, a dipeptidyl peptidase-4 inhibitor in male type 2 diabetes patients","volume":"11","author":"Heise","year":"2009","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.clinthera.2012.02.029_bib12","series-title":"Tradjenta (linagliptin) [package insert]","year":"2011"},{"key":"10.1016\/j.clinthera.2012.02.029_bib13","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1211\/jpp.61.01.0008","article-title":"Concentration-dependent plasma protein binding of the novel dipeptidyl peptidase 4 inhibitor BI 1356 due to saturable binding to its target in plasma of mice, rats and humans","volume":"61","author":"Fuchs","year":"2009","journal-title":"J Pharm Pharmacol"},{"key":"10.1016\/j.clinthera.2012.02.029_bib14","doi-asserted-by":"crossref","first-page":"829","DOI":"10.2165\/11536620-000000000-00000","article-title":"Pharmacokinetics and pharmacodynamics of single rising intravenous doses (0.5 mg-10 mg) and determination of absolute bioavailability of the dipeptidyl peptidase-4 inhibitor linagliptin (BI 1356) in healthy male subjects","volume":"49","author":"Retlich","year":"2010","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.clinthera.2012.02.029_bib15","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1124\/dmd.109.031476","article-title":"The metabolism and disposition of the oral dipeptidyl peptidase-4 inhibitor, linagliptin, in humans","volume":"38","author":"Blech","year":"2010","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.clinthera.2012.02.029_bib16","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1016\/j.clinthera.2010.06.004","article-title":"Linagliptin, a dipeptidyl peptidase-4 inhibitor in development for the treatment of type 2 diabetes mellitus: a Phase I, randomized, double-blind, placebo-controlled trial of single and multiple escalating doses in healthy adult male Japanese subjects","volume":"32","author":"Sarashina","year":"2010","journal-title":"Clin Ther"},{"key":"10.1016\/j.clinthera.2012.02.029_bib17","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1111\/j.1463-1326.2011.01458.x","article-title":"Effect of renal impairment on the pharmacokinetics of the dipeptidyl peptidase-4 inhibitor linagliptin","volume":"13","author":"Graefe-Mody","year":"2011","journal-title":"Diab Obes Metab"},{"key":"10.1016\/j.clinthera.2012.02.029_bib18","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1111\/j.1463-1326.2010.01350.x","article-title":"Effect of linagliptin monotherapy on glycaemic control and markers of beta-cell function in patients with inadequately controlled type 2 diabetes: a randomized controlled trial","volume":"13","author":"Del Prato","year":"2011","journal-title":"Diabetes Obes Metab"},{"issue":"Suppl 1","key":"10.1016\/j.clinthera.2012.02.029_bib19","first-page":"696-P","article-title":"Linagliptin monotherapy improves glycemic control in Japanese patients with T2DM over 12 weeks","volume":"59","author":"Kawamori","year":"2011","journal-title":"Diabetes"},{"key":"10.1016\/j.clinthera.2012.02.029_bib20","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1111\/j.1464-5491.2010.03131.x","article-title":"Linagliptin (BI 1356), a potent and selective DPP-4 inhibitor, is safe and efficacious in combination with metformin in patients with inadequately controlled type 2 diabetes","volume":"27","author":"Forst","year":"2010","journal-title":"Diabet Med"},{"key":"10.1016\/j.clinthera.2012.02.029_bib21","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1111\/j.1463-1326.2010.01326.x","article-title":"Safety and efficacy of linagliptin as add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study","volume":"13","author":"Taskinen","year":"2011","journal-title":"Diabetes Obes Metab"},{"issue":"Suppl 1","key":"10.1016\/j.clinthera.2012.02.029_bib22","first-page":"S326","article-title":"Safety and efficacy of linagliptin as add-on therapy to a sulphonylurea in inadequately controlled type 2 diabetes","volume":"53","author":"Lewin","year":"2010","journal-title":"Diabetologia"},{"key":"10.1016\/j.clinthera.2012.02.029_bib23","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1111\/j.1464-5491.2011.03387.x","article-title":"Efficacy and safety of linagliptin in persons with type 2 diabetes inadequately controlled by a combination of metformin and sulfonylurea: a 24-week randomized study","volume":"28","author":"Owens","year":"2011","journal-title":"Diabet Med"},{"key":"10.1016\/j.clinthera.2012.02.029_bib24","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1111\/j.1463-1326.2011.01391.x","article-title":"Efficacy and safety of initial combination therapy with linagliptin and pioglitazone in patients with inadequately controlled type 2 diabetes: a randomized, double-blind, placebo-controlled study","volume":"13","author":"Gomis","year":"2011","journal-title":"Diabetes Obes Metab"},{"issue":"Suppl 1","key":"10.1016\/j.clinthera.2012.02.029_bib25","first-page":"39-LB","article-title":"Linagliptin has similar efficacy to glimepiride but improved cardiovascular safety over 2 years in patients with type 2 diabetes inadequately controlled on metformin","volume":"60","author":"Gallwitz","year":"2011","journal-title":"Diabetes"},{"key":"10.1016\/j.clinthera.2012.02.029_bib26","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1592\/phco.30.5.463","article-title":"Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes mellitus","volume":"30","author":"Neumiller","year":"2010","journal-title":"Pharmacotherapy"},{"issue":"Suppl 1","key":"10.1016\/j.clinthera.2012.02.029_bib28","first-page":"LB9","article-title":"Cardiovascular risk with linagliptin in patients with type 2 diabetes: a pre-specified, prospective, and adjudicated meta-analysis from a large phase III program","volume":"60","author":"Johansen","year":"2011","journal-title":"Diabetes"},{"issue":"Suppl 1","key":"10.1016\/j.clinthera.2012.02.029_bib29","first-page":"1103P","article-title":"Rationale and design of the CAROLINA Trial: An active comparator cardiovascular outcome study of the DPP-4 inhibitor linagliptin in patients with type 2 diabetes at high cardiovascular risk","volume":"60","author":"Rosenstock","year":"2011","journal-title":"Diabetes"},{"key":"10.1016\/j.clinthera.2012.02.029_bib30","doi-asserted-by":"crossref","unstructured":"Graefe-Mody EU, Friedrich C, Brand T. Linagliptin has no pharmacokinetic interactions with commonly prescribed oral antidiabetes drugs. Presented at: 3rd World Congress on Controversies to Consensus in Diabetes, Obesity, and Hypertension (CODHy), Prague, Czech Republic, May 13\u201316, 2010. Abstract.","DOI":"10.14341\/2072-0351-5690"},{"key":"10.1016\/j.clinthera.2012.02.029_bib31","doi-asserted-by":"crossref","unstructured":"Graefe-Mody EU, Friedrich C, Brand T. Linagliptin has no pharmacokinetic interactions with drugs commonly used in patients with cardiac disorders. Presented at: 3rd World Congress on Controversies to Consensus in Diabetes, Obesity, and Hypertension (CODHy), Prague, Czech Republic, May 13\u201316, 2010. Abstract.","DOI":"10.14341\/2072-0351-5690"},{"key":"10.1016\/j.clinthera.2012.02.029_bib32","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s13318-011-0028-y","article-title":"Evaluation of the pharmacokinetic interaction after multiple oral doses of linagliptin and digoxin in healthy volunteers","volume":"36","author":"Friedrich","year":"2011","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"10.1016\/j.clinthera.2012.02.029_bib33","doi-asserted-by":"crossref","first-page":"367","DOI":"10.5414\/CPP48367","article-title":"Effect of linagliptin (BI 1356) on the steady-state pharmacokinetics of simvastatin","volume":"48","author":"Graefe-Mody","year":"2010","journal-title":"Int J Clin Pharmacol Ther"},{"key":"10.1016\/j.clinthera.2012.02.029_bib34","doi-asserted-by":"crossref","first-page":"643","DOI":"10.2165\/11590240-000000000-00000","article-title":"Effect of multiple oral doses of linagliptin on the steady-state pharmacokinetics of a combination oral contraceptive in healthy female adults: An open-label, two-period, fixed-sequence, multiple-dose study","volume":"31","author":"Friedrich","year":"2011","journal-title":"Clin Drug Investig"},{"key":"10.1016\/j.clinthera.2012.02.029_bib35","doi-asserted-by":"crossref","unstructured":"Rendell M, Chrysant SG, Emser A, et al. Linagliptin effectively reduces blood glucose independent of age in patients with type 2 diabetes. Presented at: 93rd Annual Meeting and Expo of The Endocrine Society (ENDO), Boston, Mass, June 4\u20137, 2011. Abstract.","DOI":"10.1210\/endo-meetings.2011.PART4.P4.P3-497"},{"issue":"Suppl 1","key":"10.1016\/j.clinthera.2012.02.029_bib36","first-page":"A114","article-title":"Safety and efficacy of linagliptin in type 2 diabetes patients with severe renal impairment","volume":"60","author":"Sloan","year":"2011","journal-title":"Diabetes"},{"key":"10.1016\/j.clinthera.2012.02.029_bib38","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1111\/j.1742-1241.2006.01178.x","article-title":"DPP-4 inhibitors and their potential role in the management of type 2 diabetes","volume":"60","author":"Barnett","year":"2006","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.clinthera.2012.02.029_bib39","doi-asserted-by":"crossref","first-page":"540","DOI":"10.4158\/EP.15.6.540","article-title":"Statement by an American Association of Clinical Endocrinologists\/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control","volume":"15","author":"Rodbard","year":"2009","journal-title":"Endocr Pract"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291812001439?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291812001439?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T08:49:01Z","timestamp":1758962941000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291812001439"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,5]]},"references-count":36,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2012,5]]}},"alternative-id":["S0149291812001439"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2012.02.029","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2012,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Review of Linagliptin for the Treatment of Type 2 Diabetes Mellitus","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2012.02.029","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 Elsevier HS Journals, Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}